INT192676

Context Info Confidence 0.46 First Reported 2006 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 14 Total Number 16 Disease Relevance 10.58 Pain Relevance 3.06

lipid binding (PTEN) cell proliferation (PTEN) cytosol (PTEN) plasma membrane (PTEN) nucleus (PTEN) enzyme binding (PTEN)

Anatomy Link Frequency foot 1 PTEN (Homo sapiens)

Pain Link Frequency Relevance Heat rheumatoid arthritis 324 99.98 Arthritis 204 99.98 spinal inflammation 186 99.98 antagonist 68 99.56 methotrexate 318 98.80 aspirin 2 92.16 Inflammation 115 90.96 psoriasis 30 87.56 Rheumatism 6 83.36 Infliximab 42 49.36

Disease Link Frequency Relevance Heat Rheumatoid Arthritis 324 99.98 Low Back Pain 198 99.98 Seronegative Spondarthritis 186 99.98 Lymphatic Filariasis 123 99.58 Cancer 294 97.88 Microsatellite Instability 94 97.88 Lymphedema 133 97.56 Endometrial Cancer 306 96.68 Disease 289 93.56 Infection 89 93.48

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Some data suggest that PTEN is associated with younger age, low stage, endometrioid histology, low histologic grade, and favorable prognosis (78% 5-year survival for patients without mutations, compared with 95% and 93% for patients with one or more mutations, resp

PTEN Binding (associated) of

1) Confidence 0.46 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.04 Pain Relevance 0

This suggests that PTEN could be a target for mutations in the context of DNA repair deficiency [13].

PTEN Binding (target) of

2) Confidence 0.36 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.45 Pain Relevance 0

No association was seen for ErbB4, PTEN or c-MYC.

PTEN Neg (No) Binding (association) of

3) Confidence 0.09 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0

PTEN loss is associated with a lower response to trastuzumab, however lapatinib appears PTEN independent and seems to maintain activity despite loss of this tumor suppressor.42,43

PTEN Binding (independent) of associated with cancer

4) Confidence 0.08 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.23 Pain Relevance 0

PTEN loss is associated with a lower response to trastuzumab, however lapatinib appears PTEN independent and seems to maintain activity despite loss of this tumor suppressor.42,43

PTEN Binding (associated) of associated with cancer

5) Confidence 0.08 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.22 Pain Relevance 0

India has faced challenges obtaining the needed levels of compliance with its mass drug administration (MDA) program to interrupt LF transmission, which utilizes diethylcarbamazine (DEC) or DEC plus albendazole.

DEC Binding (utilizes) of associated with lymphatic filariasis

6) Confidence 0.06 Published 2010 Journal PLoS Neglected Tropical Diseases Section Abstract Doc Link PMC2900179 Disease Relevance 0.58 Pain Relevance 0

India has faced challenges obtaining the needed levels of compliance with its mass drug administration (MDA) program to interrupt LF transmission, which utilizes diethylcarbamazine (DEC) or DEC plus albendazole.

DEC Binding (utilizes) of associated with lymphatic filariasis

7) Confidence 0.06 Published 2010 Journal PLoS Neglected Tropical Diseases Section Abstract Doc Link PMC2900179 Disease Relevance 0.58 Pain Relevance 0

GLM is being evaluated for the treatment of RA, PsA, and AS in several phase III trials: three trials in patients with RA treated with SC GLM, one trial in patients with RA treated with IV GLM, one trial in patients with PsA treated with SC GLM, and one trial in patients with AS treated with SC GLM.

GLM Binding (treated) of associated with spinal inflammation, rheumatoid arthritis and arthritis

8) Confidence 0.05 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 1.09 Pain Relevance 0.68

antagonist(s), and supports the use of GLM in patients who have experienced loss of efficacy, or are intolerant, to treatment with another TNF-?

GLM Binding (use) of associated with antagonist

9) Confidence 0.05 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.59 Pain Relevance 0.33

All comparisons between GLM 50 or 100 mg with placebo, including HAQ scores, ACR50, ACR70, DAS28 responders, and PASI scores were significant at week 24 (P < 0.001 for all measures).26 The effect of GLM on physical function and self-reported productivity of patients with PsA, as well as on time lost from work by caregivers of patients, was also assessed.

GLM Binding (comparisons) of associated with arthritis

10) Confidence 0.05 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.55 Pain Relevance 0.36

GLM is intended for both subcutaneous (SC) and intravenous (IV) administration.

GLM Binding (intended) of

11) Confidence 0.05 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.67 Pain Relevance 0.29

GLM is being evaluated for the treatment of RA, PsA, and AS in several phase III trials: three trials in patients with RA treated with SC GLM, one trial in patients with RA treated with IV GLM, one trial in patients with PsA treated with SC GLM, and one trial in patients with AS treated with SC GLM.

GLM Binding (treated) of associated with spinal inflammation, rheumatoid arthritis and arthritis

12) Confidence 0.05 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 1.05 Pain Relevance 0.63

GLM is being evaluated for the treatment of RA, PsA, and AS in several phase III trials: three trials in patients with RA treated with SC GLM, one trial in patients with RA treated with IV GLM, one trial in patients with PsA treated with SC GLM, and one trial in patients with AS treated with SC GLM.

GLM Binding (treated) of associated with spinal inflammation, rheumatoid arthritis and arthritis

13) Confidence 0.05 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 1.11 Pain Relevance 0.69

Mean (SE) performance scores obtained from psychomotor tests are displayed in Table 1 along with p values associated with GLM ANOVA.

GLM ANOVA Binding (associated) of

14) Confidence 0.04 Published 2010 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2819659 Disease Relevance 0 Pain Relevance 0

This result, and the favourable evolution of the condition, led to the project of treating the patient with DEC being abandoned.

DEC Binding (patient) of

15) Confidence 0.02 Published 2006 Journal Filaria J Section Body Doc Link PMC1471781 Disease Relevance 0.39 Pain Relevance 0.08

However, a combination of foot-care hygiene and DEC gave no additional benefits regarding an improvement of the lymphedema stages [8,69,70].

DEC Binding (combination) of in foot associated with lymphedema

16) Confidence 0.02 Published 2006 Journal PLoS Pathogens Section Body Doc Link PMC1564427 Disease Relevance 0.75 Pain Relevance 0

General Comments

This test has worked.